| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | VCAM1; L1CAM; VCAM 1; V CAM 1; DKFZp779G2333; CD106 |
| Entrez GeneID | 22329 |
| WB Predicted band size | Calculated MW: 81 kDa; Observed MW: 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | Recombinant protein of mouse VCAM1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于VCAM1抗体的3篇代表性文献的简要信息：
---
1. **文献名称**：*VCAM-1-targeted magnetic nanosystems for atherosclerosis imaging*
**作者**：Nahrendorf M, et al.
**摘要**：该研究开发了一种靶向VCAM1的磁性纳米颗粒造影剂，通过VCAM1抗体介导的靶向作用，成功在小鼠模型中实现了动脉粥样硬化斑块的无创性磁共振成像(MRI)，为心血管疾病的早期诊断提供了新工具。
---
2. **文献名称**：*Antibody against vascular cell adhesion molecule-1 inhibits mononuclear leukocyte infiltration in acute ischemic stroke*
**作者**：Lindsberg PJ, et al.
**摘要**：研究通过阻断VCAM1的抗体干预，显著减少了脑缺血再灌注损伤模型中的单核细胞浸润，证实了VCAM1在缺血性卒中后炎症反应中的关键作用，为抗炎治疗提供了实验依据。
---
3. **文献名称**：*VCAM-1 is a therapeutic target in metastatic prostate cancer*
**作者**：Huang J, et al.
**摘要**：该文献揭示了VCAM1在促进前列腺癌骨转移中的机制，并证明使用中和性VCAM1抗体可抑制肿瘤细胞与骨髓微环境的相互作用，显著减少小鼠模型中骨转移灶的形成。
---
4. **文献名称**：*VCAM-1-specific antibody improves endothelial function and reduces atherosclerotic plaques in ApoE−/− mice*
**作者**：Cybulsky MI, et al.
**摘要**：研究通过抗VCAM1抗体治疗载脂蛋白E缺陷(ApoE−/−)小鼠，发现其能减少血管内皮炎症反应并延缓动脉粥样硬化斑块进展，提示靶向VCAM1可能成为心血管疾病干预的新策略。
---
这些文献涵盖了VCAM1抗体在疾病诊断、炎症调控、肿瘤转移抑制及心血管治疗中的关键应用。
VCAM1 (Vascular Cell Adhesion Molecule-1), also known as CD106. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on activated endothelial cells, macrophages, and dendritic cells, playing a critical role in mediating leukocyte adhesion and transmigration during inflammatory responses. VCAM1 interacts with integrin α4β1 (VLA-4) on leukocytes, facilitating their recruitment to sites of inflammation, injury, or infection. This interaction is pivotal in chronic inflammatory diseases, atherosclerosis, autoimmune disorders, and cancer metastasis.
VCAM1 antibodies are immunological tools designed to detect, quantify, or inhibit VCAM1 protein activity in research and clinical contexts. They are widely used in techniques like flow cytometry, immunohistochemistry, and Western blotting to study VCAM1 expression patterns under pathological conditions, such as endothelial activation or tumor microenvironment remodeling. In therapeutic research, neutralizing VCAM1 antibodies have been explored to block leukocyte infiltration, potentially mitigating inflammation-driven tissue damage or cancer progression. Additionally, VCAM1-targeted imaging antibodies aid in visualizing vascular inflammation in preclinical models. Due to its involvement in immune regulation, VCAM1 remains a key biomarker and therapeutic target, with antibodies serving as essential reagents for mechanistic studies and drug development.
×
